Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses the features and increasing prevalence of frontal fibrosing alopecia, a type of scarring hair loss, and reports no new clinical results.

In this case report, a patient with alopecia areata-associated nail changes experienced normalization of nail appearance and texture after 11 months of treatment with baricitinib, suggesting that the drug may be an effective option for similar cases, although further research is needed.

This study found PRP treatment significantly increased hair count and anagen hairs in male patients with androgenetic alopecia, but there was no correlation between therapeutic response and platelet or growth factor levels.

This review highlights that poor therapeutic responses in female pattern hair loss involve multiple factors, including pharmacogenetic influences and comorbidities. It suggests a framework to improve outcomes by identifying the primary contributors and using personalized treatment strategies.

This study found that patients with alopecia areata showing low treatment burden responded better to baricitinib compared to those with higher previous systemic treatment exposure.

In this study, the authors explored the efficacy of hyperbaric oxygen therapy for typical sports injuries and cosmetic surgical wounds, finding that a hormetic dose-response relationship could explain the observed successes, contrary to prevailing expert opinion that deemed this treatment ineffective for normal wounds.

The reported treatment depths were likely incorrect and could risk patient safety.

This study highlights the role of immune dysregulation, microRNA modulation, and SIRT1 pathways in alopecia areata, suggesting antisense oligonucleotides targeting miR-485-3p as a promising therapeutic strategy for promoting hair regrowth and reducing inflammation in murine models.

This study suggests that genetic variants in the androgen receptor gene may predict which postmenopausal women with hair loss respond to finasteride therapy.

In this study, PRP injections showed comparable effectiveness to triamcinolone for alopecia areata, with a significant decrease in SALT score at one interval, and 12.5% of patients in the PRP group experienced excellent hair regrowth compared to none in the triamcinolone group.

In this study, 70 patients with alopecia areata who received intralesional triamcinolone showed a significant reduction in black dots, yellow dots, broken hair, and tapering hair, while achieving a 60% success rate in hair regrowth.

This study found that IL-1 blockers are effective for SURF and identified predictors of colchicine resistance, emphasizing the need for refined diagnostic criteria and personalized treatment due to the heterogeneity observed within SURF.

This study found that intralesional triamcinolone acetonide is effective for treating localized patchy alopecia areata, with dermoscopy aiding in early detection of clinical response and adverse effects.

This study found that oral contraceptives effectively suppressed hyperandrogenemia in most patients with hyperandrogenic-insulin-resistant acanthosis nigricans syndrome, though GnRH-a therapy was beneficial for those not responding initially.

This study found that yellow dots seen under dermatoscopy are a sensitive and specific indicator of treatment response in alopecia areata, showing significant reduction as early as four weeks.

Combining PRP with microneedling and minoxidil may help treat severe hair loss.

This letter discusses the variability in platelet-rich plasma preparation for androgenetic alopecia treatment and highlights that different methods yield varied platelet concentrations but not significant differences in growth factor secretion per platelet.

This review discusses the potential of organoids in modeling COVID-19 disease and developing therapies, without reporting new results, and highlights opportunities and challenges in their application for research.

This study found that in patients with severe alopecia areata, those who responded early to baricitinib treatment typically had a lower baseline Severity of Alopecia Tool score, shorter disease duration, and higher erythrocyte sedimentation rate, suggesting these factors may predict therapeutic success.

The authors concluded that a finasteride every other month regimen had similar maintenance effects to a daily regimen in men with androgenetic alopecia.

Use finasteride over dutasteride for hair loss; consider topical treatments and weigh risks.

This study developed a 3D bioprinted skin model to mimic pemphigus vulgaris, providing a tool to study disease mechanisms and test targeted therapies by reproducing the architecture and pathogenic disruptions of native skin.

In this retrospective observational study, researchers found that the Dean Scale showed better diagnostic accuracy than the CTCAE scale for detecting clinician-reported therapeutic responses to minoxidil in patients with anticancer therapy-induced alopecia, but both scales had limitations in recording clinically significant hair regrowth.

Delaying hair loss treatment reduces its effectiveness.

This study found that in patients with AIDS-related non-Hodgkin lymphoma undergoing targeted therapy, a positive serum albumin change rate was significantly associated with better treatment outcomes, suggesting the value of dynamic albumin monitoring and nutritional support during treatment.

The patient with Hoffman's folliculitis got better with the right treatment, leading to hair regrowth.

This study found trichoscopy to be a quick and effective method for diagnosing and monitoring tinea capitis in children, with improvements in trichoscopic features observed by week 2 and full recoveries confirmed mycologically by week 8.

This study suggests that high platelet concentrations in PRP may not be necessary for hair growth in androgenetic alopecia, and certain growth factors might negatively impact clinical outcomes.

This study found that in patients with alopecia areata, trichoscopy was a valuable tool for monitoring disease activity, severity, and therapeutic response, showing changes in trichoscopic markers that preceded improvements observed in the hair pull test.